Text Size

Development of Serologic Assays for Human Herpes Virus-8

This study has been completed.
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00395278
First received: October 31, 2006
Last updated: June 13, 2012
Last verified: May 2012
History of Changes
  Purpose

Dr. Burbelo and colleagues have developed a technique for rapidly and quantitatively detecting antibody responses in sera to a variety of pathogens using recombinant proteins. We would like to apply this technique to develop an assay for detecting antibodies to HHV-8 (KSHV, the etiologic agents of Kaposi's sarcoma, an AIDS-defining condition). We initially plan to examine samples from patients with Kaposi's sarcoma, since all those patients are almost certainly infected with HHV-8. We are thus using samples from patients with previously diagnosed Kaposi's sarcoma. The samples in question are stored at the NCI FCRF repository operated by SAIC Frederick or in Rockville, MD.


Condition
Herpesvirus 8, Human

Study Type: Observational
Official Title: Development of Serologic Assays for Human Herpes Virus-8

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 100
Study Start Date: October 2006
Detailed Description:

Dr. Burbelo and colleagues have developed a technique for rapidly and quantitatively detecting antibody responses in sera to a variety of pathogens using recombinant proteins. We would like to apply this technique to develop an assay for detecting antibodies to HHV-8 (KSHV, the etiologic agents of Kaposi's sarcoma, an AIDS-defining condition). We initially plan to examine samples from patients with Kaposi's sarcoma, since all those patients are almost certainly infected with HHV-8. We are thus using samples from patients with previously diagnosed Kaposi's sarcoma. The samples in question are stored at the NCI FCRF repository operated by SAIC Frederick or in Rockville, MD.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • Data analysis only
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00395278

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Institutes of Health Clinical Center (CC)
Investigators
Principal Investigator: Joseph A Kovacs, M.D. National Institutes of Health Clinical Center (CC)
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00395278     History of Changes
Other Study ID Numbers: 999907018, 07-CC-N018
Study First Received: October 31, 2006
Last Updated: June 13, 2012
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
KSHV
Kaposi's Sarcoma
HIV
Kaposi Sarcoma

ClinicalTrials.gov processed this record on February 24, 2013